PARP1 and acute lymphoblastic leukemia: Importantly, the growth-related role of TET1 in T-ALL could be antagonized by the clinically approved PARP inhibitor olaparib, which abrogated TET1 expression, induced loss of 5hmC, and antagonized leukaemic growth of T-ALL cells, opening a therapeutic avenue for this disease.